AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
This article was originally published in The Gray Sheet
Executive Summary
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment